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Reperfusion of the infarct-related artery(IRA) by percutaneous coronary
intervention (PCI) limits the size of the infarct
and preserves left ventricular (LV) function. In
the 1980s, various randomized trials using
thrombolytics that enrolled thousands of
patients with acute myocardial infarction with
ST-elevation (STEMI) demonstrated the clear
superiority of these agents over placebo in
terms of major cardiac events and survival.
Initially used as an alternative method of
reperfusion therapy in patients with
contraindications to thrombolysis, various
clinical trials in the 1990s subsequently
established a niche for primary PCI in patients
with STEMI. Today there is unequivocal
evidence demonstrating PCI of the IRA as the
optimal mode of therapy for STEMI.
Studies by Weaver et al. and Zilstra publish-
ed in the last decade first addressed the
comparative efficacy of the two primary
reperfusion strategies used today. In a group of
2606 patients, the mortality of PTCA was
4.4 % compared to 6.2 % in those who
received thrombolysis (p<0.02). When the
composite end-point of mortality and non-fatal
MI was, considered the difference, was even
more significant (7.2 % vs 11.9 % for
thrombolysis and PTCA respectively, p<0.01).
At this time operator experience and the
availability of facilities were the major limiting
factors. Similar conclusions were drawn from
the study of Zilstra in 395 patients comparing
PTCA with streptokinase, also demonstrating a
long-term benefit in favour of PTCA. The
results of the MITRA-MIR, study with 9906
patients, added to the evidence while
demonstrating a sustained survival benefit
compared to thrombolysis over a period of five
years in all subgroups of patients and
especially in the high-risk ones. The NRMI-2,
purportedly reflective of the real world, also
showed a significant difference in favour of
PTCA, in cardiogenic shock patients.
With the superiority of mechanical
reperfusion therapy firmly established, the next
step was the optimization of results and this
has been achieved by 1) the utilization of
stents during PCI of STEMI 2) better adjuvant
therapy and 3) decrease in the time to
reperfusion and 4) logistic improvements in the
provision of the service. 
Let us begin the with the first issue – the
utilization of stents. The BENESTENT trial
had confirmed the superiority of stents over
balloon angioplasty (BA) in elective clinical
situations and although it seemed logical to
extrapolate these findings to STEMI, there had
been no randomized trials confirming this
premise. An analysis published by Antoniucci,
composed of ‘‘trials’’ that compared PCI with
and without stents in STEMI, concluded that
there was a highly favorable outcome with the
use of stents, when the end-point included
death, re-infarction or target-vessel
revascularisation (TVR) over a 6-month follow-
up period. Among these trials, the one with the
largest number of patients, PAMI-STENT
which had 900 patients, showed a highly
significant difference (p<0.003) during seven
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months of follow-up.
An analogous situation existed with the use
of glycoprotein IIb/IIIa inhibitors, which were
found to be beneficial in patients undergoing
elective PCI. STOPAMI and ADMIRAL were
studies that assessed these patients in PCI dur-
ing STEMI. The results of STOPAMI suggested
greater myocardial salvage (using Tc-99
Sestamibi), with a concomitant decrease in the
number of events in comparison to those
receiving thrombolysis (rtPA). Besides, in
ADMIRAL, more patients who received
abciximab had patency of the IRA at the time
of PCI, and fared better than those who
received only a stent. This study enrolled 300
patients and all received stents, with or without
abciximab.
If it is evident that the utilization of stents
along with abciximab improves the short- and
long-term results of PCI in STEMI, another
equally important factor that must be consider-
ed is the time to treatment after symptoms
begin.
In the results published by Cannon, which
was an observational study involving 661
community hospitals and tertiary-care centers
in the United States, a few interesting conclu-
sions can be drawn. On the one hand, although
no increase in mortality was seen with an
increase in the time interval between the onset
of symptoms and the first balloon inflation, a
considerable increase in mortality was seen
when the door-to-balloon time exceeds two
hours. This door-to-balloon time is in the
hands of the medical team and can be consider-
ed an indicator of the quality of services provid-
ed at any particular institution. However, the
door-to-balloon time should not be the only
factor that drives the choice of PCI as the
preferred therapeutic modality in AMI. In the
PRAGUE study, there were three distinct
treatment arms – 1) thrombolysis at the
admitting hospital, 2) thrombolysis during
transport to a hospital with facilities for PCI,
and 3) direct transfer for urgent catheterization
and PCI. The combined end-point included
death, CVA, re-infarction and complications of
the therapeutic procedure. The results at 30
days demonstrated the safety of direct transfer
for PCI while demonstrating the superiority of
this strategy compared to the other two.
Another factor purported to improve the
results of PCI is the experience of the site that
provides the service. In the study by Cannon,
multivariate analysis demonstrated better858
results in those centres which performed more
than three primary PCIs a month compared to
those sites that performed between one and
three, or fewer.
These studies show that, although the
presence of on-site cardiac surgery may be
desirable, in its absence, primary PCI is still a
valuable life-saving procedure for many
patients. It is possible that the current
recommendations of the ACC/AHA will
undergo further modifications based on these
recent advances. The recommendations for
centers without on-site cardiac surgery are as
follows: 1) the patient could be transferred to a
cardiac surgical facility, if necessary, in a
period less than one hour; 2) the procedure
should be reserved for patients with STEMI or
new left bundle branch block; 3) the door-to-
balloon time should not exceed 90±30
minutes; 4) it should be performed in centers
that perform more than 36 PCIs for STEMI per
year; 5) operators should perform more than 75
PCIs/year as the primary operator.
In our center, due to logistic limitations and
limited human resources, we are unable to
offer this procedure to all patients and we have
defined subsets of patients who will be offered
this procedure. They include 1) patients in
cardiogenic shock, 2) patients with extensive
anterior wall MI as defined by the admitting
ECG/echocardiogram, and 3) young patients. If
its is clear that primary PCI is the optimal
reperfusion therapy for STEMI, neither the use
of the best stents and glycoprotein IIb/IIIa
inhibitors, nor the most experienced operator
can produce the best results if patients present
late, and this is an important element that
requires consideration.
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